Tocilizumab Biosimilar Monoclonal Antibody (IL-6R) for Research
Pre-Made Tocilizumab biosimilar, Whole mAb, Anti-IL6R Antibody: Anti-CD126/HIES5/IL-1Ra-1A/IL6Q/IL6QTL/gp80 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Tocilizumab (INN, trade name Actemra), also known as atlizumab, is an immunosuppressive drug, mainly for the treatment of rheumatoid arthritis (RA) and systemic juvenile idiopathic arthritis, a severe form of arthritis in children. It is a humanized monoclonal antibody against the interleukin-6 receptor (IL-6R). Interleukin 6 (IL-6) is a cytokine that plays an important role in immune response and is implicated in the pathogenesis of many diseases, such as autoimmune diseases, multiple myeloma and prostate cancer. It was jointly developed by Osaka University and Chugai, and was licensed in 2003 by Hoffmann-La Roche.
Order Information
| Catalog No. | Package | List Price(In USD) | Discount off | Discount Price |
|---|---|---|---|---|
| GMP-Bios-ab-584-1mg | 1mg | 243 |
Size: 1mg | 10mg | 100mg
Product Details
| Products Name (INN Index) | Pre-Made Tocilizumab biosimilar, Whole mAb, Anti-IL6R Antibody: Anti-CD126/HIES5/IL-1Ra-1A/IL6Q/IL6QTL/gp80 therapeutic antibody |
| INN Name | Tocilizumab |
| Target | IL6R |
| Format | Whole mAb |
| Derivation | Humanized |
| Species Reactivity | Human |
| CH1 Isotype | IgG1 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Approved |
| Est. Status | Active |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2004 |
| Year Recommended | 2004 |
| Companies | Assistance Publique Hopitaux de Paris;Charite - Universitatsmedizin Berlin;Chugai Pharmaceutical;Hospital for Special Surgery;JW Pharmaceutical;Roche;University Hospital Inselspital;University Hospital;Osaka University Tubingen;University of Bern;University of Pittsburgh |
| Conditions Approved | Drug hypersensitivity;Giant cell arteritis;Giant lymph node hyperplasia;Juvenile rheumatoid arthritis;Rheumatoid arthritis;Vasculitis |
| Conditions Active | Adult-onset Still's disease;Osteoarthritis;Systemic scleroderma;Amyotrophic lateral sclerosis;Dermatomyositis;Familial Mediterranean fever;Polymyalgia rheumatica;Polymyositis;Pulmonary arterial hypertension;Schnitzler syndrome;Urogenital cancer |
| Conditions Discontinued | Chronic lymphocytic leukaemia;Ankylosing spondylitis;Crohn's disease;Multiple myeloma;Pancreatic cancer;Systemic lupus erythematosus |
| Development Tech | na |
About target - IL6R
1. Protein Interleukin-6 receptor subunit alpha
2. Gene IL6R
3. Organism Homo sapiens (Human)
Function
Part of the receptor for interleukin 6. Binds to IL6 with low affinity, but does not transduce a signal (PubMed:28265003).
Signal activation necessitate an association with IL6ST. Activation leads to the regulation of the immune response, acute-phase reactions and hematopoiesis (Probable). The interaction with membrane-bound IL6R and IL6ST stimulates 'classic signaling', the restricted expression of the IL6R limits classic IL6 signaling to only a few tissues such as the liver and some cells of the immune system. Whereas the binding of IL6 and soluble IL6R to IL6ST stimulates 'trans-signaling'. Alternatively, 'cluster signaling' occurs when membrane-bound IL6:IL6R complexes on transmitter cells activate IL6ST receptors on neighboring receiver cells (Probable).
Isoform 1:
Signaling via the membrane-bound IL6R is mostly regenerative and anti-inflammatory (Probable). Drives naive CD4+ T cells to the Th17 lineage, through 'cluster signaling' by dendritic cells (By similarity).
Isoform 2:
Soluble form of IL6 receptor (sIL6R) that acts as an agonist of IL6 activity (PubMed:21990364).
The IL6:sIL6R complex (hyper-IL6) binds to IL6ST/gp130 on cell surfaces and induces signaling also on cells that do not express membrane-bound IL6R in a process called IL6 'trans-signaling'. sIL6R is causative for the proinflammatory properties of IL6 and an important player in the development of chronic inflammatory diseases (PubMed:21990364).
In complex with IL6, is required for induction of VEGF production (PubMed:12794819).
Plays a protective role during liver injury, being required for maintenance of tissue regeneration (By similarity).
'Trans-signaling' in central nervous system regulates energy and glucose homeostasis (By similarity).
Soluble interleukin-6 receptor subunit alpha:
Soluble form of IL6 receptor (sIL6R) that acts as an agonist of IL6 activity (PubMed:21990364).
The IL6:sIL6R complex (hyper-IL6) binds to IL6ST/gp130 on cell surfaces and induces signaling also on cells that do not express membrane-bound IL6R in a process called IL6 'trans-signaling'. sIL6R is causative for the proinflammatory properties of IL6 and an important player in the development of chronic inflammatory diseases (PubMed:21990364).
In complex with IL6, is required for induction of VEGF production (PubMed:12794819).
Plays a protective role during liver injury, being required for maintenance of tissue regeneration (By similarity).
'Trans-signaling' in central nervous system regulates energy and glucose homeostasis (By similarity).
Activity regulation
Classic and trans-signaling are both inhibited by tocilizumab, a humanized monoclonal antibody that blocks interleukin IL6R signaling.

